NCT06736717 - Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions

Pancreatic Cancer

Interventions

DRUG

Onvansertib

"20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle."

DRUG

NALIRIFOX

"Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle."

Trial Locations (1)

RECRUITING

The University of Kansas Cancer Center, Westwood Campus, Kansas City